title: Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes.
authors.forename: Wieland
authors.initials: W
authors.lastname: Kiess
authors.forename: Klemens
authors.initials: K
authors.lastname: Raile
authors.forename: Angela
authors.initials: A
authors.lastname: Galler
authors.forename: Thomas
authors.initials: T
authors.lastname: Kapellen
mesh_terms: D001786:Blood Glucose / Q000032:analysis / Q000187:drug effects; D003922:Diabetes Mellitus, Type 1 / Q000175:diagnosis / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007279:Injections, Subcutaneous; D007328:Insulin / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D000069057:Insulin Detemir; D007336:Insulin, Isophane / Q000008:administration & dosage*; D049528:Insulin, Long-Acting; D008297:Male; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D001786:Blood Glucose; D007328:Insulin; D049528:Insulin, Long-Acting; D000069057:Insulin Detemir; D007336:Insulin, Isophane